TITLE

Acute weight gain, gender, and therapeutic response to antipsychotics in the treatment of patients with schizophrenia

AUTHOR(S)
Ascher-Svanum, Haya; Stensland, Michael; Zhongyun Zhao; Kinon, Bruce J.
PUB. DATE
January 2005
SOURCE
BMC Psychiatry;2005, Vol. 5, p3
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background: Previous research indicated that women are more vulnerable than men to adverse psychological consequences of weight gain. Other research has suggested that weight gain experienced during antipsychotic therapy may also psychologically impact women more negatively. This study assessed the impact of acute treatment-emergent weight gain on clinical and functional outcomes of patients with schizophrenia by patient gender and antipsychotic treatment (olanzapine or haloperidol). Methods: Data were drawn from the acute phase (first 6-weeks) of a double-blind randomized clinical trial of olanzapine versus haloperidol in the treatment of 1296 men and 700 women with schizophrenia-spectrum disorders. The associations between weight change and change in core schizophrenia symptoms, depressive symptoms, and functional status were examined post-hoc for men and women and for each medication group. Core schizophrenia symptoms (positive and negative) were measured with the Brief Psychiatric Rating Scale (BPRS), depressive symptoms with the BPRS Anxiety/Depression Scale and the Montgomery-Asberg Depression Rating Scale, and functional status with the mental and physical component scores on the Medical Outcome Survey-Short Form 36. Statistical analysis included methods that controlled for treatment duration. Results: Weight gain during 6-week treatment with olanzapine and haloperidol was significantly associated with improvements in core schizophrenia symptoms, depressive symptoms, mental functioning, and physical functioning for men and women alike. The conditional probability of clinical response (20% reduction in core schizophrenia symptom), given a clinically significant weight gain (at least 7% of baseline weight), showed that about half of the patients who lost weight responded to treatment, whereas three-quarters of the patients who had a clinically significant weight gain responded to treatment. The positive associations between therapeutic response and weight gain were similar for the olanzapine and haloperidol treatment groups. Improved outcomes were, however, more pronounced for the olanzapine-treated patients, and more olanzapine-treated patients gained weight. Conclusions: The findings of significant relationships between treatment-emergent weight gain and improvements in clinical and functional status at 6-weeks suggest that patients who have greater treatment-emergent weight gain are more likely to benefit from treatment with olanzapine or haloperidol regardless of gender.
ACCESSION #
29323686

 

Related Articles

  • COMMENTARY. Vaz-Leal, Francisco J. // Evidence Based Medicine;Oct2008, Vol. 13 Issue 5, p146 

    The author reflects on the implementation of metformin plus lifestyle intervention (LSI) in patients with antipsychotic-associated weight gain. He presents a treatment comparison between patients who receive atypical antipsychotics (AAPs) and those who do not. He states low AAP doses with...

  • Sizofreni Tedavisinde Karsilanmamis Ihtiya�lar: Psikofarmakolojik Boyutlar. Karamustafalioglu, K. Oguz // Klinik Psikofarmakoloji Bulteni;DecSupplement 2, Vol. 19 Issue Supp 2, p311 

    Antipsychotics which have been used in the treatment of schizophrenia since 1950s are not effective in all symptom clusters of schizophrenia. Side effects including sedation, weight gain, hyperglycemia, extrapyramidal syndrome and hyperprolactinemia draw shadow on the efficacy of the...

  • Antipsikotiklerin G�venilirlik ve Tolerabilitesine Yeni Bir Yaklasim. G�n�l, Ali Saffet; Eker, �agdas; Simsek, Fatma // Klinik Psikofarmakoloji Bulteni;DecSupplement 2, Vol. 19 Issue Supp 2, p326 

    Despite the intensive research in the field, antipsychotics with dopamine receptor blockers are mainstay of schizophrenia treatment. Although antipsychotic drugs are very effective for the treatment, they have side effects including extrapyramidal symptoms. Extrapyramidal system side effects are...

  • Attenuating effect of reboxetine on appetite and weight gain in olanzapine-treated schizophrenia patients: a double-blind placebo-controlled study. Poyurovsky, Michael; Fuchs, Camil; Pashinian, Artashez; Levi, Aya; Faragian, Sarit; Maayan, Rachel; Gil-Ad, Irit // Psychopharmacology;Jun2007, Vol. 192 Issue 3, p441 

    Search for safe and effective strategies to diminish weight gain associated with second generation antipsychotics (SGAs) is imperative. In the present study, we sought to replicate our preliminary findings, which indicated that coadministration of the selective norepinephrine reuptake inhibitor...

  • The Role of Orexin System in Antipsychotics Induced Weight Gain. Panariello, Fabio; Javaid, Naima; Teo, Celine; Monda, Marcellino; Viggiano, Andrea; De Luca, Vincenzo // Current Psychiatry Reviews;Feb2011, Vol. 7 Issue 1, p12 

    No abstract available.

  • Drug Therapy in Schizophrenia. Ananth, J.; Parameswaran, S.; Gunatilake, S. // Current Pharmaceutical Design;Jul2004, Vol. 10 Issue 18, p2205 

    Over 40 different antipsychotic medications have been introduced around the world, 21 of which are available in the United States. The conventional antipsychotic drugs introduced in late 50s have two major groups of disadvantages, efficacy and safety. All of the atypical antipsychotic agents...

  • Optimizing Outcome with Antipsychotic Treatment in First-Episode Schizophrenia. Freudenreich, Oliver; McEvoy, Joseph P. // Clinical Schizophrenia & Related Psychoses;Oct2012, Vol. 6 Issue 3, p115 

    The initial tailoring of antipsychotic medication for an individual experiencing a first episode of psychosis (FEP) is a critical empirical process with potentially far-reaching consequences. This article reviews the results of randomized treatment trials of clinically available first-generation...

  • Weight Gain and Changes in Metabolic Variables following Olanzapine Treatment in Schizophrenia and Bipolar Disorder. Citrome, Leslie; Holt, Richard I. G.; Walker, Daniel J.; Hoffmann, Vicki Poole // Clinical Drug Investigation;2011, Vol. 31 Issue 7, p455 

    Antipsychotic therapy forms the cornerstone of treatment for people with severe mental illness. Second-generation (atypical) antipsychotics are associated with a significantly lower incidence of extrapyramidal symptoms than the typical, first-generation agents; however, changes in metabolic...

  • Neurotensin Agonists: Potential in the Treatment of Schizophrenia. Boules, Mona; Shaw, Amanda; Fredrickson, Paul; Richelson, Elliott // CNS Drugs;2007, Vol. 21 Issue 1, p13 

    Neurotensin (NT) is a neuropeptide that, for decades, has been implicated in the biology of schizophrenia. It is closely associated with, and is thought to modulate, dopaminergic and other neurotransmitter systems involved in the pathophysiology of various neuropsychiatric diseases, including...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics